PARVB deficiency alleviates cisplatin-induced tubular injury by inhibiting TAK1 signaling
Author:
Funder
National Natural Science Foundation of China
Natural Science Foundation of Guangdong Province
Shenzhen Science and Technology Innovation Program
Publisher
Springer Science and Business Media LLC
Link
https://link.springer.com/content/pdf/10.1007/s00018-024-05422-w.pdf
Reference67 articles.
1. Ghosh S, Cisplatin (2019) The first metal based anticancer drug. Bioorg Chem 88:102925
2. Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334:115–124
3. Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378
4. Khairoun M, Uffen JW, Ocak G, Koopsen R, Haitjema S, Oosterheert JJ et al (2021) The incidence, mortality and renal outcomes of acute kidney injury in patients with suspected infection at the emergency department. PLoS ONE 16:e0260942
5. Dolman ME, Harmsen S, Storm G, Hennink WE, Kok RJ (2010) Drug targeting to the kidney: advances in the active targeting of therapeutics to proximal tubular cells. Adv Drug Deliv Rev 62:1344–1357
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3